A prospective, placebo-controlled, double-blinded, randomized clinical trial evaluating cellular senescence markers, efficacy and tolerability of pre and post care skincare regimen paired with 1927nm diode fractional laser for photodamage on the face
Objectives: Assess the efficacy, tolerability, and impact on clinical and histological markers of cellular senescence with 1927nm non-ablative fractional diode laser and pre- and post-treatment topical containing 15% L-ascorbic acid, 1% vitamin E, and 0.5% ferulic acid
Introduction: The 1927 nm non-ablative fractional diode laser is used to correct photodamage. The synergistic potential of pairing it with topical antioxidants to improve results in an inclusive population has not yet been explored.
Materials / method: This was a prospective, double-blind, placebo-controlled randomized trial of 40 subjects with mild to moderate photoaging who received an antioxidant serum or a placebo. All subjects received two treatments of 1927nm diode laser to the face. Efficacy was assessed via modified Griffith scale, subject assessment, and histopathology of skin biopsies to analyze biomarkers of senescence (MMP-2, MMP-9, p16, p21, β-galactosidase).
Results: Treatment with laser and antioxidant serum showed statistically significant improvement in skin tone evenness, radiance, hyperpigmentation, and texture compared to control (p<0.05), along with higher patient satisfaction. The active group also demonstrated an inclination to reduce MMP2, MMP9, and β-galactosidase staining.
Conclusion: Combination treatment of 1927nm diode laser with a topical antioxidant enhances both clinical and molecular improvements. Through this synergic treatment, we were able to demonstrate a reduction in biomarkers of cellular senescence. This is a well-tolerated, effective treatment with high patient satisfaction.